Cephalon Pays For Option To Buy Ception Therapeutics
Cephalon Inc. (Nasdaq: CEPH) and Ception Therapeutics Inc. have signed an agreement whereby Cephalon gets the option to purchase all outstanding capital stock of Ception. Under terms of the deal, Cephalon will pay $100 million upfront, and another $250 million if it chooses to exercise the option. Ception Therapeutics is a Malvern, Pa.-based drug company whose lead candidates are anti-inflammatories. It has raised around $88 million in VC funding, from firms like Essex Woodlands Health Ventures, Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.
15 January 2009•4 mins read
